Share-based Payment Arrangement, Expense in USD of GALECTIN THERAPEUTICS INC from Q3 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
GALECTIN THERAPEUTICS INC quarterly/annual Share-based Payment Arrangement, Expense history and change rate from Q3 2020 to Q3 2025.
  • GALECTIN THERAPEUTICS INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $498K, a 3.3% decline year-over-year.
  • GALECTIN THERAPEUTICS INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2.06M, a 12.7% decline year-over-year.
  • GALECTIN THERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2024 was $2.45M, a 8.23% increase from 2023.
  • GALECTIN THERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2023 was $2.26M, a 21.1% decline from 2022.
  • GALECTIN THERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2022 was $2.87M, a 38.1% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

GALECTIN THERAPEUTICS INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $2.06M $498K -$17K -3.3% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $2.07M $500K -$238K -32.2% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $2.31M $468K -$136K -22.5% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 $2.45M $590K +$93K +18.7% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 $2.35M $515K -$71K -12.1% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 $2.43M $738K +$222K +43% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 $2.2M $604K -$58K -8.76% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 $2.26M $497K -$184K -27% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 $2.45M $586K -$95K -14% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 $2.54M $516K -$131K -20.2% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 $2.67M $662K -$196K -22.8% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 $2.87M $681K +$27K +4.13% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024
Q3 2022 $2.84M $681K +$94K +16% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 $2.75M $647K +$66K +11.4% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 $2.68M $858K +$604K +238% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 $2.08M $654K 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023
Q3 2021 $587K +$179K +43.9% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 $581K 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 $254K 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q3 2020 $408K 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021

GALECTIN THERAPEUTICS INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $2.45M +$186K +8.23% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 $2.26M -$606K -21.1% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 $2.87M +$791K +38.1% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024
2021 $2.08M +$277K +15.4% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 $1.8M 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.